BMO Capital Markets Reaffirms “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

BMO Capital Markets reaffirmed their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPTFree Report) in a research note released on Friday morning, Benzinga reports. They currently have a $170.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. UBS Group boosted their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a buy rating in a research note on Friday, March 1st. TheStreet raised shares of Sarepta Therapeutics from a d rating to a c- rating in a research note on Monday, March 4th. Barclays lifted their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an overweight rating in a research note on Thursday, February 29th. Wedbush reissued an outperform rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Evercore ISI raised their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an in-line rating in a research note on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $164.00.

Get Our Latest Stock Analysis on SRPT

Sarepta Therapeutics Trading Down 4.9 %

SRPT opened at $116.83 on Friday. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $146.68. The company has a fifty day moving average of $125.38 and a 200-day moving average of $118.71. The stock has a market cap of $11.04 billion, a PE ratio of 1,072.73 and a beta of 0.96. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue was up 63.1% compared to the same quarter last year. During the same period last year, the business posted ($1.44) EPS. On average, sell-side analysts predict that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the company. Capital International Investors increased its position in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $80,697,000. Bank of Nova Scotia purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $50,990,000. Finally, Avoro Capital Advisors LLC grew its position in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Further Reading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.